B. Riley Wealth Advisors Inc. Decreases Holdings in Moderna, Inc. (NASDAQ:MRNA)

B. Riley Wealth Advisors Inc. reduced its stake in Moderna, Inc. (NASDAQ:MRNA) by 38.0% during the second quarter, according to its most recent filing with the SEC. The fund owned 6,117 shares of the company’s stock after selling 3,754 shares during the quarter. B. Riley Wealth Advisors Inc.’s holdings in Moderna were worth $726,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. boosted its stake in Moderna by 11.9% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 11,932 shares of the company’s stock valued at $1,417,000 after acquiring an additional 1,265 shares during the last quarter. Silver Lake Advisory LLC bought a new stake in shares of Moderna in the 2nd quarter worth approximately $299,000. Nemes Rush Group LLC lifted its stake in Moderna by 18.4% in the second quarter. Nemes Rush Group LLC now owns 9,172 shares of the company’s stock valued at $1,089,000 after purchasing an additional 1,427 shares during the last quarter. Cim Investment Management Inc. bought a new position in Moderna during the second quarter valued at $203,000. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in Moderna in the second quarter worth $4,036,000. Institutional investors own 75.33% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Bank of America dropped their price target on Moderna from $130.00 to $110.00 and set a “neutral” rating on the stock in a research report on Friday, September 13th. Leerink Partners dropped their price objective on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a report on Tuesday, September 17th. JPMorgan Chase & Co. downgraded shares of Moderna from a “neutral” rating to an “underweight” rating and reduced their target price for the stock from $88.00 to $70.00 in a research note on Friday, September 13th. William Blair restated a “market perform” rating on shares of Moderna in a research note on Thursday, June 27th. Finally, HSBC upgraded shares of Moderna from a “reduce” rating to a “hold” rating and set a $82.00 price objective for the company in a research note on Wednesday, August 28th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $100.44.

Insiders Place Their Bets

In other news, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the sale, the chief financial officer now owns 8,600 shares in the company, valued at approximately $682,754. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $122.84, for a total transaction of $1,842,600.00. Following the transaction, the director now directly owns 2,254,015 shares in the company, valued at approximately $276,883,202.60. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the sale, the chief financial officer now owns 8,600 shares of the company’s stock, valued at $682,754. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 78,158 shares of company stock valued at $9,259,012 in the last quarter. Corporate insiders own 15.70% of the company’s stock.

Moderna Price Performance

Moderna stock opened at $60.20 on Friday. The business has a 50-day simple moving average of $78.45 and a 200 day simple moving average of $107.98. Moderna, Inc. has a 52 week low of $59.62 and a 52 week high of $170.47. The stock has a market cap of $23.07 billion, a price-to-earnings ratio of -3.84 and a beta of 1.67. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, topping the consensus estimate of ($3.47) by $0.14. The company had revenue of $241.00 million during the quarter, compared to analyst estimates of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. Moderna’s revenue was down 29.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($3.62) earnings per share. On average, research analysts forecast that Moderna, Inc. will post -9.86 earnings per share for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.